Stocks and Investing
Stocks and Investing
Fri, May 22, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Peter Lawson Maintained (SNDX) at Buy with Decreased Target to $23 on, May 22nd, 2020
Peter Lawson of Barclays, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Buy with Decreased Target from $25 to $23 on, May 22nd, 2020.
Peter has made no other calls on SNDX in the last 4 months.
There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 1 agrees with Peter's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lebowitz of "Morgan Stanley" Maintained at Hold with Increased Target to $22 on, Thursday, May 21st, 2020
This is the rating of the analyst that currently disagrees with Peter
- Edward White of "HC Wainwright & Co." Reiterated at Strong Buy with Increased Target to $25 on, Monday, May 11th, 2020